Related references
Note: Only part of the references are listed.Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point of Care Testing in Inflammatory Bowel Disease: Results of a Pragmatic Trial
Peter Bossuyt et al.
JOURNAL OF CROHNS & COLITIS (2022)
Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease
Samuel Raimundo Fernandes et al.
INFLAMMATORY BOWEL DISEASES (2020)
How, When, and for Whom Should We Perform Therapeutic Drug Monitoring?
Severine Vermeire et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
Joana Torres et al.
JOURNAL OF CROHNS & COLITIS (2020)
OP01 Higher vs. standard adalimumab maintenance regimens in patients with moderately to severely active ulcerative colitis: Results from the SERENE-UC maintenance study
J F Colombel et al.
Journal of Crohns & Colitis (2020)
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
Silje W. Syversen et al.
TRIALS (2020)
S0648 Clinically Adjusted vs Therapeutic Drug Monitoring Dosing Regimens With Adalimumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the SERENE-CD Maintenance Study
Silvio Danese et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
Defining Failure of Medical Therapy for Inflammatory Bowel Disease
Neil Volk et al.
INFLAMMATORY BOWEL DISEASES (2019)
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
Konstantinos Papamichael et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial
A. Strik et al.
JOURNAL OF CROHNS & COLITIS (2019)
Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease
Konstantinos Papamichael et al.
JOURNAL OF CROHNS & COLITIS (2019)
Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?
Konstantinos Papamichael et al.
CURRENT OPINION IN GASTROENTEROLOGY (2019)
Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients
Anne S. Strik et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2019)
Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease
Mark Lowenberg et al.
GASTROENTEROLOGY (2019)
Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring
Amit Assa et al.
GASTROENTEROLOGY (2019)
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Nicholas A. Kennedy et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
Christopher Andrew Lamb et al.
GUT (2019)
Practical Aspects of Proactive TDM for Anti-TNF Agents in IBD: Defining Time Points and Thresholds to Target
Camilla de Almeida Martins et al.
CROHNS & COLITIS 360 (2019)
Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab
Lieven Pouillon et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease
Anna Juncadella et al.
DIGESTIVE DISEASES AND SCIENCES (2018)
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease
Geert D'Haens et al.
GASTROENTEROLOGY (2018)
Therapeutic Drug Monitoring Guides the Management of Crohn's Patients with Secondary Loss of Response to Adalimumab
Sophie Restellini et al.
INFLAMMATORY BOWEL DISEASES (2018)
DOP046 Higher serum concentrations of vedolizumab are associated with superior endoscopic outcomes in Crohn’s disease: data from the LOVE-CD trial
S Berends et al.
Journal of Crohns & Colitis (2018)
Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study
Luisa Guidi et al.
JOURNAL OF CROHNS & COLITIS (2018)
Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease
Konstantinos Papamichael et al.
JOURNAL OF CROHNS & COLITIS (2018)
Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions
Mark G. Ward et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2018)
Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease
Yana Davidov et al.
JOURNAL OF CROHNS & COLITIS (2017)
American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases
Niels Vande Casteele et al.
GASTROENTEROLOGY (2017)
American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
Joseph D. Feuerstein et al.
GASTROENTEROLOGY (2017)
Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time
Sumin Bian et al.
INFLAMMATORY BOWEL DISEASES (2017)
Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease
Orlaith B. Kelly et al.
INFLAMMATORY BOWEL DISEASES (2017)
A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease
Johannan F. Brandse et al.
INFLAMMATORY BOWEL DISEASES (2017)
P453 Efficacy of therapeutic drug monitoring of anti-TNF therapy in the control of patients with inflammatory bowel disease
S. Bernardo et al.
Journal of Crohns & Colitis (2017)
Proactive Monitoring of Infliximab (IFX) and Adalimumab (ADA) Using LabCorp's Electrochemiluminescence Assay (ECLIA) in Inflammatory Bowel Disease Patients
Rajiv Perinbasekar et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases
N. Mitrev et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab
Konstantinos Papamichael et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
Lorant Gonczi et al.
BMC GASTROENTEROLOGY (2017)
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
Vibeke Strand et al.
BIODRUGS (2017)
Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis
B. Ungar et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals
G. R. Gunn et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2016)
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
Bella Ungar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis
Johannan F. Brandse et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis
Konstantinos Papamichael et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Accelerated Dosing of Infliximab Prevents Colectomy Within 90 Days in Only Half of Patients With Severe Ulcerative Colitis
Shail M. Govani et al.
GASTROENTEROLOGY (2016)
Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease: Distinct Clinical Implications Revealed by a Novel Assay
Roni Weisshof et al.
INFLAMMATORY BOWEL DISEASES (2016)
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
L. Peyrin-Biroulet et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab
Henit Yanai et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Biologic Concentration Testing in Inflammatory Bowel Disease
Byron P. Vaughn et al.
INFLAMMATORY BOWEL DISEASES (2015)
The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab
Hsien-Yi Chiu et al.
PLOS ONE (2015)
Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases
Xavier Roblin et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
Xavier Roblin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
Omoniyi J. Adedokun et al.
GASTROENTEROLOGY (2014)
Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial
Casper Steenholdt et al.
GUT (2014)
Tumor Necrosis Factor-Alpha Antagonists Twenty Years Later: What Do Cochrane Reviews Tell Us?
Anthony A. Akobeng et al.
INFLAMMATORY BOWEL DISEASES (2014)
Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis
Stephane Paul et al.
INFLAMMATORY BOWEL DISEASES (2014)
Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease: Results from a Pilot Observational Study
Byron P. Vaughn et al.
INFLAMMATORY BOWEL DISEASES (2014)
Tailoring anti-TNF therapy in IBD: drug levels and disease activity
Shomron Ben-Horin et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2014)
Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization
Ann Gils et al.
THERAPEUTIC DRUG MONITORING (2014)
Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
Kavinderjit S. Nanda et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
Niels Vande Casteele et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab
Fernando S. Velayos et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Long-term Outcome of Perianal Fistulizing Crohn's Disease Treated With Infliximab
Guillaume Bouguen et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease
Martin Bortlik et al.
JOURNAL OF CROHNS & COLITIS (2013)
Review article: loss of response to anti-TNF treatments in Crohn's disease
S. Ben-Horin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
Vincent Billioud et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
Nathanael L. Dirks et al.
CLINICAL PHARMACOKINETICS (2010)
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
C. H. Seow et al.
GUT (2010)
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects
Matthieu Allez et al.
JOURNAL OF CROHNS & COLITIS (2010)
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Incidence and Clinical Significance of Immunogenicity to Infliximab in Crohn's Disease: A Critical Systematic Review
Andrea Cassinotti et al.
INFLAMMATORY BOWEL DISEASES (2009)
Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies
Klaus Bendtzen et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2009)
Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease
Mark A. Ainsworth et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Antibody pharmacokinetics and pharmacodynamics
ED Lobo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
